Candidate epigenetic driver genes have been identified as either mutated across many cancers (e.g. KDM6A in over 12 cancers), having highly recurrent mutations (e.g. IDH1 R132), or having highly prevalent mutations in select tumor histologies (e.g. MLL2 in follicular lymphoma) (You and Jones, 2012). This evidence concerns the gene IDH1 and neoplasm.